PPG Industries (PPG) reported adjusted EPS (earnings per share) of $1.35 in 1Q17, an increase of approximately 6.3% over the previous year.
PPG Industries’ (PPG) Performance Coatings segment is its largest revenue contributor. The segment accounted for 56.5% of total revenue in 1Q17.
PPG Industries reported revenue of $3.57 billion in 1Q17, a 0.7% YoY (year-over-year) increase as compared to $3.54 billion in 1Q16.
Of the 29 analysts covering CSX, seven have issued a “strong buy,” 11 advise a “buy,” and ten analysts suggest a “hold” on the stock. Only one analyst issued a “sell” opinion on CSX stock.
The revenues for CSX’s Intermodal segment rose to $434.0 million in 1Q17, up 7% from $405.0 million in 1Q16.
Revenues from CSX’s Merchandise segment rose 6% to $1.8 billion in 1Q17 against $1.7 billion on a year-over-year basis.
In the first quarter of 2017, CSX’s (CSX) operating income rose 1.1% to $712.0 million from $704.0 million in 1Q16.
CSX’s coal volumes rose to 205,000 units in 1Q17, up 3% from 200,000 units in 1Q16.
Eastern US freight rail giant CSX (CSX) reported its 1Q17 earnings on April 19, 2017. CSX surprised the market with adjusted earnings per share of $0.51.
In 1Q17, UnitedHealth Group’s (UNH) Optum business reported $21.2 billion in revenues, which represents year-over-year growth of around 7.9%.
In 1Q17, UnitedHealth Group’s (UNH) UnitedHealthcare business witnessed a 2.5 million year-over-year increase in customers.
In 1Q17, UnitedHealth Group (UNH) witnessed a year-over-year increase of 70 basis points in its medical care ratio.
In 1Q17, UnitedHealth Group’s (UNH) OptumHealth segment served 6 million more people on a year-over-year basis.
UnitedHealth Group (UNH) posted its 1Q17 earnings on April 18, 2017. During the quarter, UNH reported revenues of ~$48.5 billion, which represents year-over-year growth of ~9.4%.
JNJ has received “buy” ratings from ~38% of its analysts, while ~62% of the brokerage firms have rated the company as a “hold.”
On April 20, JNJ stock was trading ~11.5% above its 52-week low of $109.32 on December 7, 2016, and ~5.5% below its 52-week high of $129.00 on March 15, 2017.
In 1Q17, priority platform sales in JNJ’s Medical Device segment grew ~6.5%, while the electrophysiology and advanced surgery businesses registered double-digit sales growth.
In 1Q17, Johnson & Johnson’s (JNJ) Medical Device segment revenues came in at ~$6.3 billion, as compared to $6.1 billion in 1Q16.
On April 18, JNJ released its 1Q17 earnings. After the announcement, the stock fell about 3% from its closing price of $125.72 on April 17.
BlackRock (BLK) continues to command a premium compared to other traditional asset managers due to its scale, operating performance, and ETF expansion.